847957-94-2

Upstream product

• 847956-83-6 (1R,3R,4S)-(4-benzyloxycarbonylamino-3-methoxymethylcyclohexyl)carbamic acid tert-butyl ester 
• 746670-92-8 benzyl (1S,2R,4R)-4-(tert-butoxycarbonylamino)-2-(hydroxymethyl)cyclohexylcarbamate 
• 848001-99-0 tert-butyl (1R,3R,4S)-4-benzyloxycarbonylamino-3-(tert-butylthiomethyl)cyclohexylcarbamate 

Downstream Products

• 848002-00-6 C₁₆H₃₂N₂O₄S 
• 848002-01-7 C₂₉H₄₇N₃O₇S₂ 
• 848002-02-8 tert-butyl (1R,3R,4S)-4-((S)-3-benzyloxycarbonylamino-2-oxopyrrolidin-1-yl)-3-(tert-butylsulfonylmethyl)cyclohexylcarbamate 
• 1610776-00-5 C₂₈H₄₀F₃N₃O₆S 
• 1610775-99-9 C₂₃H₃₂F₃N₃O₄S 

Relevant academic research and scientific papers

Alkylsulfone-containing trisubstituted cyclohexanes as potent and bioavailable chemokine receptor 2 (CCR2) antagonists

We describe novel alkylsulfones as potent CCR2 antagonists with reduced hERG channel activity and improved pharmacokinetics over our previously described antagonists. Several of these new alkylsulfones have a profile that includes functional antagonism of

Cyclic derivatives as modulators of chemokine receptor activity

The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.